Pages
Categories
Posts
-
FIRST-HALF 2023 SALES OF €5.6 M, DOWN 13 % ON S1 2022, AND CASH POSITION OF €4.3 M
-
FIRST-HALF 2023 RESULTS - SALES DOWN 13% AND RESILIENT PROFITABILITY
-
INTEGRAGEN AND BIOASTER SIGN PARTNERSHIP AGREEMENT IN GENOMICS AND TRANSCRIPTOMICS
-
INTEGRAGEN SUPPORTS THE ANTOINE LACASSAGNE CENTER IN NICE FOR A LARGE-SCALE RESEARCH PROJECT ON COLORECTAL CANCER PATIENTS
-
NEW LOOK. NEW PORTFOLIO. NEW OPPORTUNITIES.
-
POTENTIAL INVOLVEMENT OF URINARY TRACT INFECTIONS IN THE DEVELOPMENT OF BLADDER CANCER